Viatris Inc. (VTRS) Net Income CAGR:-97.37%(TTM)
Net income CAGR uses precomputed financial statement history.
Over longer horizons, Viatris Inc.'s Net Income CAGR averages -38.49% over 3 years and -31.10% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Net income CAGR shows how Viatris Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
VTRS Net Income CAGR Chart
Viatris Inc. (VTRS)
VTRS Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 20 quarters.
VTRS Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $-634.20M | $-3.51B | $-2.88B | N/A | N/A |
| 2024 | $54.70M | $-634.20M | $-688.90M | -1259.41% | N/A |
| 2023 | $2.08B | $54.70M | $-2.02B | -97.37% | -97.37% |
| 2022 | $-1.27B | $2.08B | +$3.35B | N/A | N/A |
| 2021 | $-669.90M | $-1.27B | $-599.20M | N/A | N/A |
| 2020 | $16.80M | $-669.90M | $-686.70M | -4087.50% | N/A |
| 2019 | $352.50M | $16.80M | $-335.70M | -95.23% | -95.23% |
| 2018 | $696.00M | $352.50M | $-343.50M | -49.35% | -49.35% |
| 2017 | $480.00M | $696.00M | +$216.00M | +45.00% | +45.00% |
| 2016 | $847.60M | $480.00M | $-367.60M | -43.37% | -43.37% |
| 2015 | $929.40M | $847.60M | $-81.80M | -8.80% | -8.80% |
| 2014 | $623.70M | $929.40M | +$305.70M | +49.01% | +49.01% |
| 2013 | $640.85M | $623.70M | $-17.15M | -2.68% | -2.68% |
| 2012 | $536.81M | $640.85M | +$104.04M | +19.38% | +19.38% |
| 2011 | $345.12M | $536.81M | +$191.69M | +55.55% | +55.55% |
| 2010 | $232.57M | $345.12M | +$112.54M | +48.39% | +48.39% |
| 2009 | $-196.08M | $232.57M | +$428.65M | N/A | N/A |
| 2008 | $-1.52B | $-196.08M | +$1.32B | N/A | N/A |
| 2007 | $184.54M | $-1.52B | $-1.70B | -922.23% | N/A |
| 2006 | $203.59M | $184.54M | $-19.05M | -9.36% | -9.36% |
| 2005 | $334.61M | $203.59M | $-131.02M | -39.16% | -39.16% |
Quarterly Net Income: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $176.40M | — | — |
| Q4 2025 | -$340.10M | -165.3% | +34.2% |
| Q3 2025 | -$128.20M | — | — |
| Q2 2025 | -$4.60M | +99.8% | +98.6% |
| Q1 2025 | -$3.04B | -489.0% | — |
| Q4 2024 | -$516.50M | — | +32.5% |
| Q3 2024 | $94.80M | — | -71.4% |
| Q2 2024 | -$326.40M | — | — |
| Q1 2024 | $113.90M | — | -49.3% |
| Q4 2023 | -$765.60M | — | — |
| Q3 2023 | $331.60M | +25.6% | -6.4% |
| Q2 2023 | $264.00M | +17.5% | -15.9% |
| Q1 2023 | $224.70M | -77.8% | -43.7% |
| Q4 2022 | $1.01B | +185.4% | — |
| Q3 2022 | $354.30M | +12.9% | +13.7% |
| Q2 2022 | $313.90M | -21.4% | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith